HUMAW
Humacyte IncKey Statistics
About Humacyte Inc
Humacyte Inc. is a pioneering biotechnology firm at the forefront of developing and commercializing universally implantable human tissues, prominently featuring its human acellular vessel (HAV) technology. By leveraging cutting-edge manufacturing techniques and robust clinical trial advancements, Humacyte is poised to transform vascular and regenerative medicine, effectively addressing significant healthcare challenges. The company's commitment to enhancing patient outcomes through innovative tissue-based solutions positions it for strategic collaborations and notable growth opportunities within the regenerative medicine sector, ultimately aiming to reshape the future of healthcare.
Fundamentals
| Revenue (TTM) | $2.02M |
| Gross Profit (TTM) | $-81.72M |
| EBITDA | $-105.19M |
| Operating Margin | -5704.00% |
| Return on Equity | -409.50% |
| Return on Assets | -51.50% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.05 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -4.30% |
| Shares Outstanding | 0 |
| Float | $196.13M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HUMAW and any ticker you trade — then tracks every position and per-strategy win rate.